Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 10/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 4/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062724 | 0.89 | KDR (0.46) | KDRFGFR1BRAFMAPK14RAF1 | |
| SCHEMBL3625799 | 0.86 | KDR (0.44) | KDRFGFR1BRAFMAPK14RAF1 | |
| SCHEMBL5064666 | 0.84 | KDR (0.52) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL3666008 | 0.84 | KDR (0.48) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL3665903 | 0.84 | KDR (0.48) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL5067416 | 0.83 | KDR (0.51) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL3634715 | 0.83 | KDR (0.49) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL5064651 | 0.83 | KDR (0.51) | KDRFGFR1BRAFMAPK14TNNI3K | |
| SCHEMBL5063747 | 0.83 | KDR (0.47) | KDRFGFR1BRAFFLT1 | |
| SCHEMBL5064647 | 0.81 | KDR (0.48) | KDRFGFR1BRAFMAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | KDR 263/4885FGFR1 202/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.